Evidence map›Paper›PMID 21179458›Full record

ArticlePloS one2010

Resveratrol induces growth arrest and apoptosis through activation of FOXO transcription factors in prostate cancer cells.

Qinghe Chen, Suthakar Ganapathy, Karan P Singh, Sharmila Shankar, Rakesh K Srivastava

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed
8.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 189 citations in OpenAlex.

  1. Review
  2. Review
  3. AMPK-Targeting Effects of (-)-Epicatechin Gallate fromInternational journal of molecular sciences · 2025
    Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. The Nutriepigenome.Genes · 2023
    Review
  11. Review
  12. Review
  13. Review
  14. The role of Wnt/mTOR signaling in spinal cord injury.Journal of clinical orthopaedics and trauma · 2022
    Review
  15. Article
  16. Targeting of cancer cell death mechanisms by resveratrol: a review.Apoptosis : an international journal on programmed cell death · 2021
    Review
  17. FOXO3a and Its Regulators in Prostate Cancer.International journal of molecular sciences · 2021
    Review
  18. Review
  19. Review
  20. Article

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 1 country.

Qinghe ChenVirginia Bioinformatics Institute, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, United States of America.
Suthakar Ganapathy
Karan P Singh
Sharmila Shankar
Rakesh K Srivastava
The University of Kansas Cancer Center · USThe University of Texas Health Science Center at San Antonio · USUniversity of Kansas Medical Center · USUniversity of North Texas Health Science Center · USVirginia Tech · US

Funding

Mechanisms of Chemoprevention by ResveratrolR01CA114469 · NCI · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI SRIVASTAVA, RAKESH K. · 2005 to 2009
$726k
NCI NIH HHS R01 CA114469NCI NIH HHS R01CA114469
6 · The paper itself

Abstract

backgroundResveratrol, a naturally occurring phytopolyphenol compound, has attracted extensive interest in recent years because of its diverse pharmacological characteristics. Although resveratrol possesses chemopreventive properties against several cancers, the molecular mechanisms by which it inhibits cell growth and induces apoptosis have not been clearly understood. The present study was carried out to examine whether PI3K/AKT/FOXO pathway mediates the biological effects of resveratrol. METHODOLOGY/PRINCIPAL

findingsResveratrol inhibited the phosphorylation of PI3K, AKT and mTOR. Resveratrol, PI3K inhibitors (LY294002 and Wortmannin) and AKT inhibitor alone slightly induced apoptosis in LNCaP cells. These inhibitors further enhanced the apoptosis-inducing potential of resveratrol. Overexpression of wild-type PTEN slightly induced apoptosis. Wild type PTEN and PTEN-G129E enhanced resveratrol-induced apoptosis, whereas PTEN-G129R had no effect on proapoptotic effects of resveratrol. Furthermore, apoptosis-inducing potential of resveratrol was enhanced by dominant negative AKT, and inhibited by wild-type AKT and constitutively active AKT. Resveratrol has no effect on the expression of FKHR, FKHRL1 and AFX genes. The inhibition of FOXO phosphorylation by resveratrol resulted in its nuclear translocation, DNA binding and transcriptional activity. The inhibition of PI3K/AKT pathway induced FOXO transcriptional activity resulting in induction of Bim, TRAIL, p27/KIP1, DR4 and DR5, and inhibition of cyclin D1. Similarly, resveratrol-induced FOXO transcriptional activity was further enhanced when activation of PI3K/AKT pathway was blocked. Over-expression of phosphorylation deficient mutants of FOXO proteins (FOXO1-TM, FOXO3A-TM and FOXO4-TM) induced FOXO transcriptional activity, which was further enhanced by resveratrol. Inhibition of FOXO transcription factors by shRNA blocked resveratrol-induced upregulation of Bim, TRAIL, DR4, DR5, p27/KIP1 and apoptosis, and inhibition of cyclin D1 by resveratrol. CONCLUSION/SIGNIFICANCE: These data suggest that FOXO transcription factors mediate anti-proliferative and pro-apoptotic effects of resveratrol, in part due to activation of extrinsic apoptosis pathway.

Indexed as

ApoptosisGene Expression Regulation, NeoplasticAndrostadienesAntineoplastic AgentsCell Line, TumorCell ProliferationChromonesForkhead Box Protein O1Forkhead Transcription FactorsHumansMaleMorpholinesMutationPhosphatidylinositol 3-KinasesProstatic NeoplasmsProto-Oncogene Proteins c-akt2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-oneAndrostadienesAntineoplastic AgentsChromonesForkhead Box Protein O1Forkhead Transcription FactorsFOXO1 protein, humanMorpholinesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktResveratrolStilbenesWortmannin

Identifiers

PMID21179458
PMCPMC3001855
OpenAlexW1998410775

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.